Efficacy and Safety of NNC0487-0111 s.c. Once-weekly in Participants With Overweight or Obesity, and Knee Osteoarthritis (AMAZE 6)
Latest Information Update: 09 Apr 2026
At a glance
- Drugs Zenagamtide (Primary)
- Indications Obesity
- Focus Registrational; Therapeutic Use
- Acronyms AMAZE 6
- Sponsors Novo Nordisk
Most Recent Events
- 09 Apr 2026 New trial record